Hemogenyx Pharmaceuticals (LSE:HEMO) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 29, 2026)


LSE:HEMO Hemogenyx Pharmaceuticals PLC LSE:HEMO
31 GF Score
Price £7.80
! 2 Warning Signs
View Full Analysis

What is Hemogenyx Pharmaceuticals Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Hemogenyx Pharmaceuticals's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

LSE:HEMO vs VRTX, REGN, ALNY: Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, Hemogenyx Pharmaceuticals's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hemogenyx Pharmaceuticals Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hemogenyx Pharmaceuticals's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Hemogenyx Pharmaceuticals's Margin of Safety % (DCF Earnings Based) falls into.


LSE:HEMO
31GF Score
Hemogenyx Pharmaceuticals PLC LSE:HEMO
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hemogenyx Pharmaceuticals Business Description

Address 6 Heddon Street, London, GBR, W1B 4BT
Hemogenyx Pharmaceuticals PLC is clinical-stage biotechnology focused on the discovery, development and commercialisation of treatments relating to the treatment of blood cancers, certain solid cancers, autoimmune diseases, and viral infections. The products under development are designed to address a range of problems that occur with current standard of care treatments. The Group has one reportable segment, the discovery, development, and commercialisation of treatments relating to blood and immune system disorders and viral infections, and administrative functions in the United Kingdom. It has its presence in United Kingdom; and United States.
31GF Score

Get the complete analysis for LSE:HEMO

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

£7.80
Price